s23-00723: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Endometrial Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma
    2. Has received prior systemic, platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy, either separately or in combination, for endometrial carcinoma or carcinosarcoma

You may not be eligible for this study if the following are true:

    1. Has neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas
    2. Is a candidate for curative-intent surgery or curative-intent radiotherapy at the time of enrollment



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.